275.26
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$269.93
Offen:
$268.05
24-Stunden-Volumen:
328.05K
Relative Volume:
0.93
Marktkapitalisierung:
$6.11B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-10.96
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
+2.88%
1M Leistung:
-19.23%
6M Leistung:
-16.13%
1J Leistung:
+22.07%
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MDGL
Madrigal Pharmaceuticals Inc
|
275.26 | 5.94B | 0 | -518.67M | -438.32M | -25.12 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
2024-04-22 | Eingeleitet | BofA Securities | Underperform |
2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
2024-03-06 | Eingeleitet | Citigroup | Buy |
2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
2022-12-20 | Bestätigt | Oppenheimer | Outperform |
2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
2022-12-19 | Bestätigt | Piper Sandler | Overweight |
2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
2021-10-07 | Eingeleitet | Jefferies | Buy |
2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2021-05-20 | Fortgesetzt | Goldman | Buy |
2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
2020-01-09 | Hochstufung | UBS | Neutral → Buy |
2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
2019-06-25 | Eingeleitet | Stifel | Hold |
2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
2019-01-23 | Eingeleitet | UBS | Neutral |
2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
2018-09-04 | Eingeleitet | Citigroup | Buy |
2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK
When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com
In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years - AOL.com
Transcript : Madrigal Pharmaceuticals, Inc.Special Call - marketscreener.com
Where are the Opportunities in (MDGL) - news.stocktradersdaily.com
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN
MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus
MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times
Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.
Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - Yahoo Finance
Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra (NASDAQ:MDGL) - Seeking Alpha
Billionaire John Paulson’s 10 Stocks with Huge Upside Potential - Insider Monkey
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
(MDGL) Trading Signals - news.stocktradersdaily.com
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Stron - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating - marketscreener.com
Madrigal Pharmaceuticals (MDGL) Receives Increased Price Target from Analyst | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Madrigal Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Madrigal: Q1 Earnings Snapshot - Huron Daily Tribune
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Zacks Investment Research
Madrigal Pharmaceuticals Q1 Loss Narrows - marketscreener.com
Earnings call transcript: Madrigal Pharmaceuticals beats Q1 2025 EPS forecasts - Investing.com
Madrigal Pharmaceuticals Inc Q1 2025 Earnings: Revenue Surpasses - GuruFocus
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
Madrigal Pharmaceuticals (MDGL) Reports Strong Q1 Revenue Exceed - GuruFocus
Madrigal’s MASH drug sales again top Wall Street projections - Yahoo Finance
Madrigal stock holds neutral as 1Q revenue beats estimates By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (MDGL) to Present Key Findings at EASL - GuruFocus
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):